[
  {
    "ts": null,
    "headline": "GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View",
    "summary": "GSK's Q3 earnings and revenue beat expectations, powered by HIV and oncology growth, prompting the company to lift its 2025 outlook.",
    "url": "https://finnhub.io/api/news?id=52e063996463b426f039a994f6805dfd8580271516400b52f4572ce63aa1b5f5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761752880,
      "headline": "GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View",
      "id": 137258470,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "GSK's Q3 earnings and revenue beat expectations, powered by HIV and oncology growth, prompting the company to lift its 2025 outlook.",
      "url": "https://finnhub.io/api/news?id=52e063996463b426f039a994f6805dfd8580271516400b52f4572ce63aa1b5f5"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced plans to initiate the first head-to-head study comparing FcRn blockers for patients with generalized myasthenia gravis (gMG), which aims to affirm IMAAVY™ (nipocalimab-aahu) as the FcRn blocker of choice for appropriate gMG patients. The EPIC study design and Vibrance-MG Phase 2/3 long-term extension (LTE) data are among 38 abstracts the Company will present at the 2025 Myasthenia Gravis Foundation of America (MGFA) Scientific Session and the America",
    "url": "https://finnhub.io/api/news?id=32a1fca05c55ef01615c338ca9600c78092bdd6ee9e3e18eac4c10c030a44ea3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761739500,
      "headline": "Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting",
      "id": 137247866,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced plans to initiate the first head-to-head study comparing FcRn blockers for patients with generalized myasthenia gravis (gMG), which aims to affirm IMAAVY™ (nipocalimab-aahu) as the FcRn blocker of choice for appropriate gMG patients. The EPIC study design and Vibrance-MG Phase 2/3 long-term extension (LTE) data are among 38 abstracts the Company will present at the 2025 Myasthenia Gravis Foundation of America (MGFA) Scientific Session and the America",
      "url": "https://finnhub.io/api/news?id=32a1fca05c55ef01615c338ca9600c78092bdd6ee9e3e18eac4c10c030a44ea3"
    }
  },
  {
    "ts": null,
    "headline": "Best Dividend Kings: October 2025",
    "summary": "Dividend Kings are underperforming SPY in 2025, with a year-to-date return gap of 13.10%, but 12 Kings remain ahead of the index. Read more here.",
    "url": "https://finnhub.io/api/news?id=e88d07ba5881f7fac15aa768a04affc18b86c74fac7aa9fc28bbd4c57b8e173a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761714686,
      "headline": "Best Dividend Kings: October 2025",
      "id": 137246617,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2148089915/image_2148089915.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Dividend Kings are underperforming SPY in 2025, with a year-to-date return gap of 13.10%, but 12 Kings remain ahead of the index. Read more here.",
      "url": "https://finnhub.io/api/news?id=e88d07ba5881f7fac15aa768a04affc18b86c74fac7aa9fc28bbd4c57b8e173a"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Price Target Increased by 10.96% to 204.02",
    "summary": "Johnson & Johnson (JNJ) Price Target Increased by 10.96% to 204.02",
    "url": "https://finnhub.io/api/news?id=09feab3eebd0ebe3598f49e45e72c94cbed2adca3bb592d39e03f0a7ec15604b",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761703985,
      "headline": "Johnson & Johnson (JNJ) Price Target Increased by 10.96% to 204.02",
      "id": 137241806,
      "image": "",
      "related": "JNJ",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=09feab3eebd0ebe3598f49e45e72c94cbed2adca3bb592d39e03f0a7ec15604b"
    }
  },
  {
    "ts": null,
    "headline": "Freedom Capital Downgrades Johnson & Johnson (JNJ) to Hold Despite Strong Q3 Results",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the Best Dividend Stocks for the Best Retirement Portfolio. On October 22, Free⁠dom Capital Mark‍ets has lowered i⁠ts‍ rating on Johnson & Johnson (NYSE:JNJ) from B‍uy to Hold, even as it raised the stock’s price tar⁠get fro‌m $180 to $19​0 f⁠oll​owing a solid third-qua⁠rte​r⁠ perform⁠ance. The healt‌hcare company […]",
    "url": "https://finnhub.io/api/news?id=1079309583ac2e9054ff73b7cf85c9537868fe62dde4d1dd410647843a33c904",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761702148,
      "headline": "Freedom Capital Downgrades Johnson & Johnson (JNJ) to Hold Despite Strong Q3 Results",
      "id": 137243340,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is included among the Best Dividend Stocks for the Best Retirement Portfolio. On October 22, Free⁠dom Capital Mark‍ets has lowered i⁠ts‍ rating on Johnson & Johnson (NYSE:JNJ) from B‍uy to Hold, even as it raised the stock’s price tar⁠get fro‌m $180 to $19​0 f⁠oll​owing a solid third-qua⁠rte​r⁠ perform⁠ance. The healt‌hcare company […]",
      "url": "https://finnhub.io/api/news?id=1079309583ac2e9054ff73b7cf85c9537868fe62dde4d1dd410647843a33c904"
    }
  }
]